Search clinical trials for: Tamsulosin and solifenacin

Total 272056 results

Timothy Boone, MD, PhD
Astellas Pharma US, Inc.

Completed

Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms (LUTS)

Lower Urinary Tract Symptoms

United States
Jeil Pharmaceutical Co., Ltd.

Completed

Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH

Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia

Korea, Republic of
Astellas Pharma Europe B.V.

Completed

Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms (Neptune)

Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia

Belgium, Italy, France, Austria, United Kingdom, Netherlands, Hungary, Russian Federation, Poland, Slovakia, Czech Republic, Belarus, Germany
Mansoura University

Completed

Comparison of Tamsulosin and Solifenacin in Treatment of Ureteral Stent Symptoms

Relieve of Ureteral Stent Symptoms

Egypt
Astellas Pharma Inc

Completed

Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction

Lower Urinary Tract Symptoms | Bladder Outlet Obstruction

United States, Czech Republic, Poland, Hungary, Belgium, Germany
Soonchunhyang University Hospital

Completed

The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB)

Overactive Bladder

Korea, Republic of
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate How Tamsulosin (at 1 Dose) and Solifenacin (at 2 Different Doses) Are Taken up From the Intestine, Distributed Through the Body and Eliminated From the Body When Administered in Combination as a Single Tablet (Called EC905)

Healthy Subjects | Pharmacokinetics | EC905 | Multiple Dose

United Kingdom
Jeil Pharmaceutical Co., Ltd.

Completed

The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers.

Overactive Bladder | Benign Prostatic Hyperplasia | LUTS(Lower Urinary Tract Symptoms)
Astellas Pharma Inc

Completed

A Study With Combination Treatment (Tamsulosin Hydrochloride and Solifenacin Succinate) in Male Patients With LUTS/BPH (SATURN)

Lower Urinary Tract Symptoms | Prostatic Hyperplasia

France, Poland, Germany, Spain, Finland, Netherlands, Russian Federation, Czech Republic, Hungary, Norway, Denmark, Slovakia, Sweden, Austria, Portugal, United Kingdom
Jeil Pharmaceutical Co., Ltd.

Completed

Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin

Overactive Bladder | Benign Prostatic Hyperplasia | LUTS

Korea, Republic of
Astellas Pharma Europe B.V.

Completed

Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms (Neptune II)

Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia

Belgium, Italy, France, Austria, United Kingdom, Netherlands, Poland, Slovakia, Belarus, Germany, Czechia
Astellas Pharma Inc

Completed

Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia

Overactive Bladder | Benign Prostatic Hyperplasia | Benign Prostatic Hypertrophy

Japan
IlDong Pharmaceutical Co Ltd

Unknown

Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia

Benign Prostate Hyperplasia

Korea, Republic of
Mansoura University

Active, not recruiting

Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB

Overactive Bladder | Benign Prostatic Hyperplasia

Egypt
Astellas Pharma Europe B.V.

Completed

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects

Healthy Subjects | Pharmacokinetics | Drug-Drug Interaction (DDI)

Germany
Astellas Pharma Inc

Completed

A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men. (VICTOR)

Urinary Incontinence

United States
Astellas Pharma Europe B.V.

Completed

A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin

Healthy Subjects | Pharmacokinetics | EC905

United Kingdom
Astellas Pharma Taiwan, Inc.

Completed

Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms

Overactive Bladder | Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia (BPH)

Taiwan
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate Whether Verapamil Has an Effect on the Uptake and Elimination of Solifenacin and Tamsulosin When Administered in a Combination Tablet

Healthy Subjects | Drug-Drug Interaction (DDI)

France
Astellas Pharma Europe B.V.

Completed

EC905 Pharmacokinetic Profile Study

Healthy | Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia | Phase 1

Netherlands
Astellas Pharma Europe B.V.

Completed

A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

Pediatric | Neurogenic Detrusor Overactivity

United States, Belgium, Korea, Republic of, Philippines, Poland, United Kingdom
Astellas Pharma Europe Ltd.

Completed

Vesitirim™ in Men Postmarketing Observational Study (VIM)

Overactive Bladder (OAB) | Lower Urinary Tract Symptoms (LUTS)

Ireland
Pierre Fabre Medicament

Completed

PERmixon® in LUTS Evaluation Study (PERLES) (PERLES)

Benign Prostatic Hyperplasia (BPH)

France, Italy, Germany, Spain, Czech Republic
China Medical University Hospital

Recruiting

Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder

Sjogren's Syndrome | Overactive Bladder Syndrome

Taiwan
Mansoura University

Recruiting

Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms

Ureteral Stent | Stent Related Symptoms

Egypt
Astellas Pharma Inc

Completed

Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers

Healthy Volunteers | Pharmacokinetics of Solifenacin Succinate | Bioavailability of Solifenacin Succinate

United States
Hanmi Pharmaceutical Company Limited

Completed

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With BPH

Benign Prostate Hyperplasia

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers

Overactive Bladder
Astellas Pharma Inc

Completed

Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents

Urinary Bladder, Overactive

Sweden, United Kingdom, Belgium, Denmark
Astellas Pharma Europe B.V.

Completed

A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076 (LEOPARD)

Urinary Bladder, Overactive

Belgium, United States, Brazil, Canada, Denmark, Former Serbia and Montenegro, Korea, Republic of, Mexico, Norway, Philippines, Poland, South Africa, Sweden, Turkey, Ukraine, United Kingdom
Center Eugene Marquis

Terminated

Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer (VesiCaP)

Overactive Bladder

France
Lahey Clinic
Astellas Pharma US, Inc.

Terminated

Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder

Overactive Bladder

United States
National Taiwan University Hospital

Unknown

Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients

Overactive Bladder Syndrome

Taiwan
Astellas Pharma Inc

Completed

A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation

Healthy Volunteers | Pharmacokinetics of Solifenacin Succinate

United States
Boehringer Ingelheim

Completed

Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male.

Prostatic Hyperplasia
Menoufia University

Completed

Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe LUTS Due to BPH

Prostatic Neoplasms | Prostate Disease | Prostate Hypertrophy | Prostate Obstruction

Egypt
Boehringer Ingelheim

Completed

Pharmacokinetics, Safety and Tolerability of Tamsulosin Hydrochloride in Children With Voiding Disorders

Urination Disorders
Lawson Health Research Institute

Not yet recruiting

Prevention of Post Operative Urinary Retention After Thoracic Surgery Trial (PrePOURTS)

Urinary Retention Postoperative

Canada
KYU-SUNG LEE
Astellas Pharma Korea, Inc.

Completed

A Study to Evaluate Add on Effect of Solifenacin in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks

Overactive Bladder

Korea, Republic of
Loyola University
Astellas Pharma US, Inc.

Completed

Bacterial Genomic Sequencing in Overactive Bladder

Overactive Bladder

United States
Astellas Pharma Inc
Astellas Pharma Korea, Inc.

Completed

A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment (RESORT-2)

Over Active Bladder

Korea, Republic of
Seattle Urology Research Center

Unknown

Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)

Nocturia | Urinary Urgency | Urinary Frequency

United States
Loyola University
Astellas Pharma US, Inc.

Completed

Incontinence & Intimate Partners: Assessing the Contribution of Treatment (IIMPACT)

Urge Urinary Incontinence

United States
Pierre Fabre Medicament

Completed

Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia) (PERMIN)

Benign Prostatic Hyperplasia (BPH)

France, Spain, Portugal, Italy
Hackensack Meridian Health

Recruiting

Post-operative Urinary Retention (POUR) Following Thoracic Surgery (POUR)

Urinary Retention

United States
Astellas Pharma China, Inc.

Completed

A Study to Compare How Tamsulosin is Absorbed to the Body After Administration of Two Types of Tamsulosin Formulation Under Fed and Fasted Conditions in Chinese Healthy Subjects

Healthy | Pharmacokinetics of Tamsulosin Hydrochloride

China
Dong-A ST Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder

Overactive Bladder

Korea, Republic of
Astellas Pharma Inc

Completed

Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome

Urinary Tract Diseases

Japan
Astellas Pharma Inc

Completed

Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome

Urinary Tract Diseases

Japan
Astellas Pharma Inc

Completed

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder. (SHRINK)

Overactive Bladder | Detrusor Overactivity

Belgium, Norway, Spain, Sweden, Italy, Czech Republic, Hungary, France, Canada, Germany, Austria, United Kingdom, Bulgaria, Russian Federation, United States, Poland, Slovakia, Turkey, Israel, Romania

3

Subscribe